Strategies to improve radiotherapy with targeted drugs

Key Points

  • Two complementary ways to improve radiotherapy are to increase the killing of tumour cells and to decrease damage to surrounding normal tissues. Central to success is finding and exploiting genetic or microenvironmental differences between normal and malignant tissues in each individual patient.

  • Modulating DNA repair: owing to genetic instability, tumours are often defective in one aspect of DNA repair but usually have backup pathways for accomplishing repair. Attacking these backup pathways can render the tumour radiosensitive while leaving the normal tissue relatively resistant. Increasing numbers of such examples are being discovered.

  • Modulating cell cycle checkpoints: tumours are often defective in one of the cell cycle checkpoints (such as the G1/S checkpoint). Inhibiting remaining checkpoints can leave tumours with less repair time, resulting in greater cell kill than in normal tissues.

  • Modulating signal transduction pathways: the PI3K–AKT, nuclear factor-κB (NF-κB), MAPK pathways and others, can all mediate radioresistance and are often aberrantly activated in tumours. Attacking these pathways with specific inhibitors is a promising avenue for increasing the radiosensitivity of tumours.

  • Modulating the microenvironment: tumours often contain radioresistant and chemoresistant hypoxic cells. Several methods are available to attack or exploit tumour hypoxia, leading to tumour-specific effects. Tumour vasculature can also be attacked in ways that increase the response to ionizing radiation.

  • Modulating normal tissue damage: a variety of strategies have shown promise in ameliorating ionizing radiation damage to normal tissues, including protection with radical scavengers, stimulating recovery with cytokines, modifying the p53 response, reducing the negative effects of inflammatory cascades and oxidative stress, and stem cell therapy.

  • The future: for any new strategies, it will be essential to define not only effects on the tumour but also effects on normal tissues. In addition, to realize personalized treatments, rapid and robust methods to assess deregulated pathways need to be developed. These then need to be combined with the development of a larger arsenal of agents inhibiting specific pathways, so that the most effective radiomodifying drug can be selected for each patient.

Abstract

Radiotherapy is used to treat approximately 50% of all cancer patients, with varying success. The dose of ionizing radiation that can be given to the tumour is determined by the sensitivity of the surrounding normal tissues. Strategies to improve radiotherapy therefore aim to increase the effect on the tumour or to decrease the effects on normal tissues. These aims must be achieved without sensitizing the normal tissues in the first approach and without protecting the tumour in the second approach. Two factors have made such approaches feasible: namely, an improved understanding of the molecular response of cells and tissues to ionizing radiation and a new appreciation of the exploitable genetic alterations in tumours. These have led to the development of treatments combining pharmacological interventions with ionizing radiation that more specifically target either tumour or normal tissue, leading to improvements in efficacy.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Ionizing radiation-induced DNA damage repair.
Figure 2: Application of checkpoint inhibitors to increase the radiosensitivity of cancer cells.
Figure 3: Targeting signal transduction.
Figure 4: Targeting the microenvironment.
Figure 5: Strategies to reduce early or late ionizing radiation injury in normal tissues.

References

  1. 1

    Delaney, G., Jacob, S., Featherstone, C. & Barton, M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104, 1129–1137 (2005).

  2. 2

    Hoppe, R, Phillips, T. L. & Roach, M. Leibel and Phillips Textbook of Radiation Oncology Third Edition (Elsevier, 2010).

  3. 3

    Bhide, S. A. & Nutting, C. M. Recent advances in radiotherapy. BMC Med. 8,25 (2010).

  4. 4

    Nordsmark, M. et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. 77, 18–24 (2005).

  5. 5

    Kim, J. J. & Tannock, I. F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nature Rev. Cancer 5, 516–525 (2005).

  6. 6

    Withers, H. R., Taylor, J. M. & Maciejewski, B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27, 131–146 (1988).

  7. 7

    West, C. M., Davidson, S. E., Roberts, S. A. & Hunter, R. D. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br. J. Cancer 68, 819–823 (1993).

  8. 8

    Ahn, G. O. et al. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc. Natl Acad. Sci. USA 107, 8363–8368 (2010).

  9. 9

    Kioi, M. et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120, 694–705 (2010).

  10. 10

    Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 461, 1071–1078 (2009).

  11. 11

    Kastan, M. B. DNA damage responses: mechanisms and roles in human disease: 2007 G. H. A. Clowes Memorial Award Lecture. Mol. Cancer Res. 6, 517–524 (2008).

  12. 12

    Lobrich, M. & Jeggo, P. A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nature Rev. Cancer 7, 861–869 (2007).

  13. 13

    Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability--an evolving hallmark of cancer. Nature Rev. Mol. Cell Biol. 11, 220–228 (2010).

  14. 14

    Bartkova, J. et al. ATM activation in normal human tissues and testicular cancer. Cell Cycle 4, 838–845 (2005).

  15. 15

    Jeggo, P. & Lavin, M. F. Cellular radiosensitivity: how much better do we understand it? Int. J. Radiat. Biol. 85, 1061–1081 (2009).

  16. 16

    O'Driscoll, M. & Jeggo, P. A. The role of double-strand break repair - insights from human genetics. Nature Rev. Genet. 7, 45–54 (2006).

  17. 17

    Almeida, K. H. & Sobol, R. W. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair (Amst). 6, 695–711 (2007).

  18. 18

    Caldecott, K. W. Single-strand break repair and genetic disease. Nature Rev. Genet. 9, 619–631 (2008).

  19. 19

    Dianov, G. L., O'Neill, P. & Goodhead, D. T. Securing genome stability by orchestrating DNA repair: removal of radiation-induced clustered lesions in DNA. Bioessays 23, 745–749 (2001).

  20. 20

    Jenner, T. J., Fulford, J. & O'Neill, P. Contribution of base lesions to radiation-induced clustered DNA damage: implication for models of radiation response. Radiat. Res. 156, 590–593 (2001).

  21. 21

    Veuger, S. J., Curtin, N. J., Richardson, C. J., Smith, G. C. & Durkacz, B. W. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 63, 6008–6015 (2003).

  22. 22

    Hickson, I. et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64, 9152–9159 (2004).

  23. 23

    Rainey, M. D., Charlton, M. E., Stanton, R. V. & Kastan, M. B. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 68, 7466–7474 (2008).

  24. 24

    Chalmers, A. J., Lakshman, M., Chan, N. & Bristow, R. G. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin. Radiat. Oncol. 20, 274–281 (2010).

  25. 25

    Noel, G. et al. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol. Cancer Ther. 5, 564–574 (2006).

  26. 26

    Dungey, F. A., Loser, D. A. & Chalmers, A. J. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int. J. Radiat. Oncol. Biol. Phys. 72, 1188–1197 (2008).

  27. 27

    Calabrese, C. R. et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 96, 56–67 (2004).

  28. 28

    Albert, J. M. et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res. 13, 3033–3042 (2007). A demonstration of enhancing the ionizing radiation effects on tumours by adding PARP inhibitors in preclinical models.

  29. 29

    Verheij, M., Vens, C. & van Triest, B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist. Updat. 13, 29–43 (2010).

  30. 30

    Simeonov, A. et al. Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. PLoS One 4, e5740 (2009).

  31. 31

    Abbotts, R. & Madhusudan, S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat Rev. 36, 425–435 (2010).

  32. 32

    Higgins, G. S. et al. A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown. Cancer Res. 70, 2984–2993 (2010).

  33. 33

    Higgins, G. S. et al. Overexpression of POLQ confers a poor prognosis in early breast cancer patients. Oncotarget. 1, 175–184 (2010).

  34. 34

    Lemee, F. et al. DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc. Natl Acad. Sci. USA 107, 13390–13395 (2010).

  35. 35

    Mukherjee, B. et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res. 69, 4252–4259 (2009). One of the few in vitro examples that shows differential radiosensitization by exploiting genetic alterations in tumour cells.

  36. 36

    Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nature Rev. Cancer 8, 193–204 (2008). Timely Review addressing the potential of exploiting DNA repair defects in tumours for therapy.

  37. 37

    Kaelin, W. G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nature Rev. Cancer 5, 689–698 (2005).

  38. 38

    Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).

  39. 39

    Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).

  40. 40

    Kennedy, R. D. et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J. Clin. Invest. 117, 1440–1449 (2007).

  41. 41

    Williamson, C. T. et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol. Cancer Ther. 9, 347–357 (2010).

  42. 42

    McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109–8115 (2006).

  43. 43

    Vens, C. & Begg, A. C. Targeting base excision repair as a sensitization strategy in radiotherapy. Semin. Radiat. Oncol. 20, 241–249 (2010).

  44. 44

    Neijenhuis, S., Verwijs-Janssen, M., van den Broek, L. J., Begg, A. C. & Vens, C. Targeted radiosensitization of cells expressing truncated DNA Polymerase β. Cancer Res. 70, 8706–8714 (2010). First proof-of-principle demonstration of exploiting BER deficiencies to improve radiotherapy.

  45. 45

    Bristow, R. G. & Hill, R. P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nature Rev. Cancer 8, 180–192 (2008).

  46. 46

    Chan, N. et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 68, 605–614 (2008).

  47. 47

    Bindra, R. S. et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res. 65, 11597–11604 (2005).

  48. 48

    Bindra, R. S. et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol. Cell Biol. 24, 8504–8518 (2004).

  49. 49

    McEllin, B. et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 70, 5457–5464 (2010).

  50. 50

    Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315–322 (2009).

  51. 51

    Dedes, K. J. et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci. Transl. Med. 2, 53ra75 (2010).

  52. 52

    Nitta, M. et al. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS ONE 5, e10767 (2010).

  53. 53

    Wouters, B. G., Giaccia, A. J., Denko, N. C. & Brown, J. M. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res. 57, 4703–4706 (1997).

  54. 54

    Slichenmyer, W. J., Nelson, W. G., Slebos, R. J. & Kastan, M. B. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53, 4164–4168 (1993).

  55. 55

    Bucher, N. & Britten, C. D. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br. J. Cancer 98, 523–528 (2008).

  56. 56

    Mack, P. C. et al. Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells. Radiat. Res. 162, 623–634 (2004).

  57. 57

    Syljuasen, R. G. et al. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res. 64, 9035–9040 (2004).

  58. 58

    O'Connor, M. J., Martin, N. M. & Smith, G. C. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 26, 7816–7824 (2007).

  59. 59

    Zabludoff, S. D. et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 7, 2955–2966 (2008).

  60. 60

    Morgan, M. A. et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70, 4972–4981 (2010). A study of the combination of cell cycle checkpoint inhibitors with ionizing radiation, which has been taken the furthest in preclinical testing to date.

  61. 61

    Boutros, R., Lobjois, V. & Ducommun, B. CDC25 phosphatases in cancer cells: key players? Good targets? Nature Rev. Cancer 7, 495–507 (2007).

  62. 62

    Brezak, M. C., Kasprzyk, P. G., Galcera, M. O., Lavergne, O. & Prevost, G. P. CDC25 inhibitors as anticancer agents are moving forward. Anticancer Agents Med. Chem. 8, 857–862 (2008).

  63. 63

    Golding, S. E. et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 8, 2894–2902 (2009).

  64. 64

    Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T. & D'Andrea, A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol. Cancer 8, 24 (2009).

  65. 65

    Kirshner, J. et al. Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res. 66, 10861–10869 (2006). First demonstration that TGFβ is involved in ATM activation in epithelial cells, with consequences for radiosensitivity.

  66. 66

    Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211–225 (2000).

  67. 67

    LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B. & Dennis, P. A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11, 32–50 (2008).

  68. 68

    Kim, I. A. et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res. 65, 7902–7910 (2005).

  69. 69

    Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567–578 (2006). First large randomized Phase III clinical trial showing the efficacy of a molecularly targeted agent combined with radiotherapy.

  70. 70

    Bonner, J. A. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21–28 (2010).

  71. 71

    Bianco, C. et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8, 3250–3258 (2002).

  72. 72

    Feng, F. Y. et al. Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin. Cancer Res. 13, 2512–2518 (2007).

  73. 73

    Krause, M., Gurtner, K., Deuse, Y. & Baumann, M. Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors. Int. J. Radiat. Biol. 85, 943–954 (2009).

  74. 74

    Russo, S. M. et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 50, 183–193 (2001).

  75. 75

    Li, F. & Sethi, G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta. 1805, 167–180 (2010).

  76. 76

    Nakanishi, C. & Toi, M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nature Rev. Cancer. 5, 297–309 (2005).

  77. 77

    Veuger, S. J., Hunter, J. E. & Durkacz, B. W. Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance. Oncogene 28, 832–842 (2009).

  78. 78

    Tsuboi, Y. et al. Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kappa B activation in human glioma cell lines. J. Neurosurg. 110, 594–604 (2009).

  79. 79

    Sandur, S. K. et al. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int. J. Radiat. Oncol. Biol. Phys. 75, 534–542 (2009).

  80. 80

    Golding, S. E. et al. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res. 67, 1046–1053 (2007).

  81. 81

    Kriegs, M. et al. The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair (Amst). 9, 889–897 (2010).

  82. 82

    Andarawewa, K. L., Paupert, J., Pal, A. & Barcellos-Hoff, M. H. New rationales for using TGFbeta inhibitors in radiotherapy. Int. J. Radiat. Biol. 83, 803–811 (2007).

  83. 83

    Wiegman, E. M., Blaese, M. A., Loeffler, H., Coppes, R. P. & Rodemann, H. P. TGFbeta-1 dependent fast stimulation of ATM and p53 phosphorylation following exposure to ionizing radiation does not involve TGFbeta-receptor I signalling. Radiother. Oncol. 83, 289–295 (2007).

  84. 84

    Dent, P., Yacoub, A., Fisher, P. B., Hagan, M. P. & Grant, S. MAPK pathways in radiation responses. Oncogene 22, 5885–5896 (2003).

  85. 85

    Beg, A. A. & Baltimore, D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274, 782–784 (1996).

  86. 86

    Brown, J. M. & Attardi, L. D. The role of apoptosis in cancer development and treatment response. Nature Rev. Cancer 5, 231–237 (2005).

  87. 87

    Toulany, M. et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin. Cancer Res. 12, 4119–4126 (2006).

  88. 88

    Dittmann, K. et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem. 280, 31182–31189 (2005). First demonstration of a direct link between the EGFR signal transduction pathway and DSB repair.

  89. 89

    Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225–239 (2007).

  90. 90

    Wouters, B. G. & Brown, J. M. Cells at intermediate oxygen levels can be more important than the “hypoxic fraction” in determining tumor response to fractionated radiotherapy. Radiat. Res. 147, 541–550 (1997).

  91. 91

    Tredan, O., Galmarini, C. M., Patel, K. & Tannock, I. F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 99, 1441–1454 (2007).

  92. 92

    Wang, G. L., Jiang, B. H., Rue, E. A. & Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 92, 5510–5514 (1995).

  93. 93

    Rouschop, K. M. & Wouters, B. G. Regulation of autophagy through multiple independent hypoxic signaling pathways. Curr. Mol. Med. 9, 417–424 (2009).

  94. 94

    Chi, J. T. et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 3, e47 (2006).

  95. 95

    Winter, S. C. et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 67, 3441–3449 (2007).

  96. 96

    Seigneuric, R. et al. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother. Oncol. 83, 374–382 (2007).

  97. 97

    Kjellen, E., Joiner, M. C., Collier, J. M., Johns, H. & Rojas, A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother. Oncol. 22, 81–91 (1991).

  98. 98

    Kaanders, J. H., Bussink, J. & van der Kogel, A. J. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol. 3, 728–737 (2002).

  99. 99

    Dische, S., Rojas, A., Rugg, T., Hong, A. & Michael, B. D. Carbogen breathing: a system for use in man. Br. J. Radiol. 65, 87–90 (1992).

  100. 100

    Kaanders, J. H. & van der Maazen, R. W. A convenient and reliable method for carbogen breathing in man. Radiother. Oncol. 29, 341–343 (1993).

  101. 101

    Khandelwal, S. R. et al. Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation. Am. J. Physiol. 265, H1450–H1453 (1993).

  102. 102

    Amorino, G. P. et al. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13. Radiat. Res. 156, 294–300 (2001).

  103. 103

    Scott, C., Suh, J., Stea, B., Nabid, A. & Hackman, J. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am. J. Clin. Oncol. 30, 580–587 (2007).

  104. 104

    Overgaard, J. et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5–85 Radiother. Oncol. 46, 135–146 (1998). First demonstration in a randomized Phase III trial of the efficacy of a hypoxic cell radiosensitizer, showing the validity of the approach and the importance of hypoxia as a negative prognostic factor in head and neck cancer.

  105. 105

    Brown, J. M., Diehn, M. & Loo, B. W. Jr. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys. 78, 323–327 (2010).

  106. 106

    Brown, J. M. & Koong, A. Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J. Natl. Cancer Inst. 83, 178–185 (1991).

  107. 107

    Rischin, D. et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J. Clin. Oncol. 28, 2989–2995 (2010).

  108. 108

    Hicks, K. O. et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin. Cancer Res. 16, 4946–4957 (2010).

  109. 109

    Rouschop, K. M. et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J. Clin. Invest. 120, 127–141 (2010).

  110. 110

    Qayum, N. et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res. 69, 6347–6354 (2009).

  111. 111

    Cohen-Jonathan, E. et al. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res. 61, 2289–2293 (2001).

  112. 112

    Carmeliet, P. et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485–490 (1998).

  113. 113

    Ahn, G. O. & Brown, J. M. Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives. Cell Cycle. 8, 970–976 (2009). Demonstration of the importance of vasculogenesis and how its inhibition can dramatically increase the ionizing radiation response of tumours.

  114. 114

    Ahn, G. O. & Brown, J. M. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis. 12, 159–164 (2009).

  115. 115

    Ahn, G. O. & Brown, J. M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13, 193–205 (2008).

  116. 116

    Garcia-Barros, M. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155–1159 (2003).

  117. 117

    Stone, H. B. et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3–4, 2003. Radiat. Res. 162, 711–728 (2004).

  118. 118

    Patt, H. M., Tyree, E. B., Straube, R. L. & Smith, D. E. Cysteine protection against X irradiation. Science 110, 213–214 (1949).

  119. 119

    Weiss, J. F. & Landauer, M. R. History and development of radiation-protective agents. Int. J. Radiat. Biol. 85, 539–573 (2009).

  120. 120

    Denekamp, J., Michael, B. D., Rojas, A. & Stewart, F. A. Radioprotection of mouse skin by WR-2721: the critical influence of oxygen tension. Int. J. Radiat. Oncol. Biol. Phys. 8, 531–534 (1982).

  121. 121

    Hensley, M. L. et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 27, 127–145 (2009).

  122. 122

    Antonadou, D. et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 57, 402–408 (2003).

  123. 123

    Komaki, R. et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int. J. Radiat. Oncol. Biol. Phys. 58, 1369–1377 (2004).

  124. 124

    Andreassen, C. N., Grau, C. & Lindegaard, J. C. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin. Radiat. Oncol. 13, 62–72 (2003).

  125. 125

    Dorr, W., Heider, K. & Spekl, K. Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF. Int. J. Radiat. Biol. 81, 557–565 (2005).

  126. 126

    Farrell, C. L. et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 58, 933–939 (1998).

  127. 127

    Khan, W. B., Shui, C., Ning, S. & Knox, S. J. Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. Radiat. Res. 148, 248–253 (1997).

  128. 128

    Chen, L. et al. The protective effect of recombinant human keratinocyte growth factor on radiation-induced pulmonary toxicity in rats. Int. J. Radiat. Oncol. Biol. Phys. 60, 1520–1529 (2004).

  129. 129

    Spielberger, R. et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 351, 2590–2598 (2004).

  130. 130

    Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B. & Evan, G. I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214–217 (2006).

  131. 131

    Komarov, P. G. et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733–1737 (1999).

  132. 132

    Burdelya, L. G. et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320, 226–230 (2008).

  133. 133

    Okunieff, P. et al. In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice. Radiat. Res. 150, 204–211 (1998).

  134. 134

    Paris, F. et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293–297 (2001). This paper challenged the traditional paradigm of epithelial cell death as the determinant of ionizing radiation-induced intestinal damage and presents data in support of endothelial cell apoptosis as the prime cause of this damage.

  135. 135

    Fuks, Z. et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 54, 2582–2590 (1994).

  136. 136

    Schuller, B. W. et al. No significant endothelial apoptosis in the radiation-induced gastrointestinal syndrome. Int. J. Radiat. Oncol. Biol. Phys. 68, 205–210 (2007).

  137. 137

    Potten, C. S. Radiation, the ideal cytotoxic agent for studying the cell biology of tissues such as the small intestine. Radiat. Res. 161, 123–136 (2004).

  138. 138

    Tee, P. G. & Travis, E. L. Basic fibroblast growth factor does not protect against classical radiation pneumonitis in two strains of mice. Cancer Res. 55, 298–302 (1995).

  139. 139

    Kirsch, D. G. et al. p53 Controls Radiation-Induced Gastrointestinal Syndrome in Mice Independent of Apoptosis. Science 327, 593–596 (2010). This paper shows that selective deletion of pro-apoptotic genes from the gastrointestinal epithelium or endothelium did not protect mice from developing gastrointestinal syndrome, suggesting instead a mechanism regulated by p53 but independent of apoptosis.

  140. 140

    Hauer-Jensen, M., Wang, J. & Denham, J. W. Bowel injury: current and evolving management strategies. Semin. Radiat. Oncol. 13, 357–371 (2003).

  141. 141

    Martin, M., Lefaix, J. & Delanian, S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int. J. Radiat. Oncol. Biol. Phys. 47, 277–290 (2000).

  142. 142

    Bentzen, S. M. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nature Rev. Cancer 6, 702–713 (2006).

  143. 143

    Zheng, H., Wang, J., Koteliansky, V. E., Gotwals, P. J. & Hauer-Jensen, M. Recombinant soluble transforming growth factor beta type II receptor ameliorates radiation enteropathy in mice. Gastroenterology 119, 1286–1296 (2000).

  144. 144

    Anscher, M. S., Thrasher, B., Rabbani, Z., Teicher, B. & Vujaskovic, Z. Antitransforming growth factor-beta antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. Int. J. Radiat. Oncol. Biol. Phys. 65, 876–881 (2006).

  145. 145

    Haydont, V. et al. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin. Cancer Res. 13, 5331–5340 (2007).

  146. 146

    Verheij, M., Stewart, F. A., Oussoren, Y., Weening, J. J. & Dewit, L. Amelioration of radiation nephropathy by acetylsalicylic acid. Int. J. Radiat. Biol. 67, 587–596 (1995).

  147. 147

    Wang, J. et al. Short-term inhibition of ADP-induced platelet aggregation by clopidogrel ameliorates radiation-induced toxicity in rat small intestine. Thromb. Haemost. 87, 122–128 (2002).

  148. 148

    Wang, J. et al. Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure. J. Thromb. Haemost. 2, 2027–2035 (2004).

  149. 149

    Glantz, M. J. et al. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 44, 2020–2027 (1994).

  150. 150

    Ozturk, B., Egehan, I., Atavci, S. & Kitapci, M. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 58, 213–219 (2004).

  151. 151

    Hauer-Jensen, M., Fink, L. M. & Wang, J. Radiation injury and the protein C pathway. Crit. Care Med. 32, S325–S330 (2004).

  152. 152

    Zhao, W. et al. Administration of the peroxisomal proliferator-activated receptor gamma agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment. Int. J. Radiat. Oncol. Biol. Phys. 67, 6–9 (2007).

  153. 153

    Williams, J. P. et al. Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. Radiat. Res. 161, 560–567 (2004).

  154. 154

    Wang, J. et al. Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int. J. Radiat. Oncol. Biol. Phys. 68, 1483–1490 (2007).

  155. 155

    Irwin, B. C. et al. Calcium channel blockers may radionsensitize patients to radiation proctitis while statins, NSAIDs may radioprotect: a case-control study. Gastroenterology Abstr. 130 (Suppl. 2), A-460 (2006).

  156. 156

    Moulder, J. E., Fish., B. L. & Cohen, E. P. Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Curr. Pharm. Des 13, 1317–1325 (2007).

  157. 157

    Robbins, M. E. & Diz, D. I. Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. Int. J. Radiat. Oncol. Biol. Phys. 64, 6–12 (2006).

  158. 158

    Kim, J. H. et al. Modification of radiation injury by ramipril, inhibitor of angiotensin-converting enzyme, on optic neuropathy in the rat. Radiat. Res. 161, 137–142 (2004).

  159. 159

    Cohen, E. P. et al. Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int. J. Radiat. Oncol. Biol. Phys. 70, 1546–1551 (2008).

  160. 160

    Wang, L. W. et al. Can. angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis? Radiat. Res. 153, 405–410 (2000).

  161. 161

    Kang, S. K. et al. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 57, 1056–1066 (2003).

  162. 162

    Rabbani, Z. N. et al. Overexpression of extracellular superoxide dismutase reduces acute radiation induced lung toxicity. BMC Cancer 5, 59 (2005).

  163. 163

    Zhang, X. et al. Radioprotection in vitro and in vivo by minicircle plasmid carrying the human manganese superoxide dismutase transgene. Hum. Gene Ther. 19, 820–826 (2008).

  164. 164

    Lefaix, J. L. et al. Successful treatment of radiation-induced fibrosis using Cu/Zn-SOD and Mn-SOD: an experimental study. Int. J. Radiat. Oncol. Biol. Phys. 35, 305–312 (1996).

  165. 165

    Delanian, S. et al. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother. Oncol. 32, 12–20 (1994).

  166. 166

    Delanian, S. & Lefaix, J. L. Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. Semin. Radiat. Oncol. 17, 99–107 (2007).

  167. 167

    Vujaskovic, Z. et al. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic. Biol. Med. 33, 857–863 (2002).

  168. 168

    Delanian, S., Porcher, R., Balla-Mekias, S. & Lefaix, J. L. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J. Clin. Oncol. 21, 2545–2550 (2003).

  169. 169

    Delanian, S., Chatel, C., Porcher, R., Depondt, J. & Lefaix, J. L. Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a Pentoxifylline-Tocopherol-Clodronate Combination (PENTOCLO): a Phase II Trial. Int. J. Radiat. Oncol. Biol. Phys. 16 Jul 2010 (doi: 10.1016/j.ijrobp.2010.03.029).

  170. 170

    Dong, C. & Goldschmidt-Clermont, P. J. Endothelial progenitor cells: a promising therapeutic alternative for cardiovascular disease. J. Interv. Cardiol. 20, 93–99 (2007).

  171. 171

    Young, P. P., Vaughan, D. E. & Hatzopoulos, A. K. Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog. Cardiovasc. Dis. 49, 421–429 (2007).

  172. 172

    Mummery, C. L., Davis, R. P. & Krieger, J. E. Challenges in using stem cells for cardiac repair. Sci. Transl. Med. 2, 27ps17 (2010).

  173. 173

    Coppes, R. P., van der Goot, A. & Lombaert, I. M. Stem cell therapy to reduce radiation-induced normal tissue damage. Semin. Radiat. Oncol. 19, 112–121 (2009).

  174. 174

    Epperly, M. W. et al. Bone marrow origin of cells with capacity for homing and differentiation to esophageal squamous epithelium. Radiat. Res. 162, 233–240 (2004).

  175. 175

    Lombaert, I. M. et al. Mobilization of bone marrow stem cells by granulocyte colony-stimulating factor ameliorates radiation-induced damage to salivary glands. Clin. Cancer Res. 12, 1804–1812 (2006). This paper provides the first evidence that stem cells mobilized from bone marrow can localize to ionizing radiation-damaged organs (salivary gland) and promote functional and morphological recovery in the damaged tissue.

  176. 176

    Lombaert, I. M. et al. Cytokine treatment improves parenchymal and vascular damage of salivary glands after irradiation. Clin. Cancer Res. 14, 7741–7750 (2008).

  177. 177

    Francois, S. et al. Human mesenchymal stem cells favour healing of the cutaneous radiation syndrome in a xenogenic transplant model. Ann. Hematol. 86, 1–8 (2007).

  178. 178

    Semont, A. et al. Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis. Cell Death Differ. 17, 952–961 (2010).

  179. 179

    Lataillade, J. J. et al. New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal stem cell therapy. Regen. Med. 2, 785–794 (2007).

  180. 180

    Lombaert, I. M. et al. Rescue of salivary gland function after stem cell transplantation in irradiated glands. PLoS ONE 3, e2063 (2008).

  181. 181

    Rezvani, M. et al. Modification of radiation myelopathy by the transplantation of neural stem cells in the rat. Radiat. Res. 156, 408–412 (2001).

  182. 182

    Brown, J. M. & Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408–1416 (1998).

  183. 183

    Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).

  184. 184

    Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).

  185. 185

    Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790–800 (2009).

  186. 186

    International network of cancer genome projects. Nature 464, 993–998 (2010).

  187. 187

    Kim, T. J. et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br. J. Cancer. 94, 1678–1682 (2006).

  188. 188

    Gupta, A. K. et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res. 8, 885–892 (2002).

  189. 189

    Willers, H. et al. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol. Cancer Res. 7, 1304–1309 (2009). Development of a clinically useful functional assay for HR capacity, useful for patient selection for PARP inhibitors or crosslinking agents.

  190. 190

    Bentzen, S. M. Radiobiological considerations in the design of clinical trials. Radiother. Oncol. 32, 1–11 (1994).

  191. 191

    Diez, P., Vogelius, I. S. & Bentzen, S. M. A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 77, 1066–1071 (2010).

Download references

Acknowledgements

The authors would like to thank the Dutch Cancer Society (KWF Kankerbestrijding) and the Netherlands Cancer Institute for long-term financial support.

Author information

Correspondence to Adrian C. Begg.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

DATABASES

National Cancer Institute Drug Dictionary 

Amifostine

AZD7762

captopril

carbogen

cetuximab

cisplatin

efaproxiral

gefitinib

palifermin

pentoxifylline

tirapazamine

Glossary

Hypoxia

Lack of oxygen. Cells begin to become resistant to ionizing radiation at <1% oxygen (mild hypoxia) and are fully resistant at 0.01% oxygen (severe hypoxia). Solid tumours often contain a proportion of mildly and severely hypoxic cells.

Mitotic catastrophe

Caused by the attempt to segregate aberrant chromosomes. Failure of mitosis can activate programmed cell death (apoptosis). Problems completing mitosis and the resulting loss of genetic material can further reduce clonogenic survival.

Unfolded protein response

(UPR). A signalling cascade that is activated when unfolded or misfolded proteins are detected, which increases under hypoxia. It aims to stop protein translation and increase correct folding; failure can lead to cell death.

Electron affinic

A measure of the ability of a neutral atom to take up an electron. Oxygen is a powerful radiosensitizer because of its ability to capture electrons ejected by irradiation from DNA and other biomolecules, leaving them damaged and reactive and resulting in chemical bond breakage.

Hypofractionation

Conventional radiotherapy with curative intent is given in fractions of 1.8–2.0Gy daily on weekdays up to 30–35 times. Hypofractionation refers to giving a lower number of fractions larger than 2.0Gy, which is more effective per unit dose owing to the curvature of the ionizing radiation dose–response curve.

Hypoxia modification

The use of strategies to reduce the negative effect of hypoxia on the sensitivity to ionizing radiation, including selective killing or radiosensitization of hypoxic cells.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Begg, A., Stewart, F. & Vens, C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11, 239–253 (2011). https://doi.org/10.1038/nrc3007

Download citation

Further reading